Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending February 20, 2008. The report serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibility (PDMRs), specifically detailing share-based awards granted on February 19, 2008. The filing does not contain financial results, operational metrics, or general business updates for the period.
Key Financial Metrics
The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial data points present relate to the valuation of equity awards:
- Share Price (Feb 19, 2008): GBP 11.47 per Ordinary share.
- ADS Price (Feb 19, 2008): US$ 44.75 per American Depository Share (ADS).
- Option Exercise Price: GBP 11.47 (Ordinary) or US$ 44.75 (ADS).
Material Changes
The material change reported is the grant of new equity compensation awards to senior executives. There are no reported changes to financial performance or corporate structure in this document.
Guidance, Outlook, and Management Commentary
The filing outlines the performance conditions attached to the new awards, which serve as management's implicit targets for the 2008-2010 period:
- Performance Share Plan: Vesting is contingent on Total Shareholder Return (TSR) relative to a comparator group of 14 pharmaceutical companies (including Pfizer, Merck, and Novartis) over three years (Jan 1, 2008 – Dec 31, 2010). No awards vest if GSK ranks below the median; 100% vests if ranked 1st or 2nd.
- Share Option Plan: Vesting depends on Earnings Per Share (EPS) growth exceeding the Retail Price Index (RPI) by at least 3% per annum over the same three-year period. Full vesting requires EPS growth exceeding RPI by 6% per annum.
- Retention Award: A one-off award of 111,750 ADSs was granted to Mr. Chris Viehbacher (President, US Pharmaceuticals), vesting in tranches in 2009 and 2011 based on continued employment and performance.
Important Facts for Investor Verification
- Grant Date: All awards were granted on February 19, 2008, with a vesting date of February 19, 2011 (except the retention award).
- Recipients: Awards were made to Executive Directors (including Mr. A.P. Witty and Mr. J.S. Heslop) and other PDMRs.
- Performance Hurdles: Investors should monitor GSK's TSR ranking against the specified 14 peers and its EPS growth relative to RPI to determine the potential dilution from these awards.
- Share Conversion: One ADS equals two Ordinary shares; awards were granted in both instruments.
- Dividend Accrual: Dividends accrue on the shares during the vesting period and vest only to the extent that the underlying shares vest.